SynaptixBio secures FDA Rare Paediatric Disease designation to develop treatments for TUBB4a leukodystrophy
February 10, 2023Research and Development
SynaptixBio, a UK-based biotech firm, has been granted FDA Rare Paediatric Disease (RPD) designation – an accolade which encourages the …
AbbVie expects 37% decline in Humira sales following new biosimilars hitting the US market
February 10, 2023Sales and Marketing
AbbVie Inc has announced that it expects to see a 37% decline in sales of its flagship rheumatoid arthritis drug …
FDA grants full approval to GSK for mismatch repair-deficient endometrial cancer treatment
February 10, 2023Medical Communications
GSK announced that its treatment for recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer has been granted full approval by …
RQ Bio Strengthens Board with Industry-leading Infectious Disease Experts Joining as Non-Executive Directors
February 9, 2023Business Services
LONDON, UK, 9 February 2023 — RQ Bio is scaling up at speed, with the appointment of Non-Executive Directors, Dr …
Stand Up To Cancer announces four teams dedicated to increasing diversity in clinical trials
February 9, 2023Medical Communications
Stand Up To Cancer (SU2C) has announced four teams that will focus on increasing diversity in early phase cancer clinical …
FDA grants RMAT designation for Mesoblast’s chronic low back pain treatment
February 9, 2023Medical Communications
Mesoblast Ltd, an Australian regenerative medicine company leading in allogeneic cellular medicines for inflammatory diseases, announced that its treatment for …
FDA approves Regeneron’s Eylea for the treatment of retinopathy of prematurity in infants
February 9, 2023Research and Development
The FDA has approved Regeneron Pharmaceuticals’ Eylea (aflibercept) injection for the treatment of retinopathy of prematurity (ROP) in preterm infants. …
Garuda Therapeutics closes series B funding with $62m
February 9, 2023Sales and Marketing
Cambridge-based Garuda Therapeutics announced it closed a $62m series B funding round to support its off-the-shelf, self-renewing blood stem cell …
The First Women in Leadership Network to Support Diversity, Equality and Inclusion across the Life Sciences Industry launched in Denmark
February 9, 2023Business Services
9 February 2023, Denmark: Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior …
Redx Provides Progress Update on RXC007 Clinical Programme
February 9, 2023Business Services
Alderley Park, UK, 9 February 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 9, 2023Business Services
Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), a pioneer …
Availability of Sanofi’s Nexviadyme®▼(avalglucosidase alfa) provides NHS with new treatment for Pompe disease
February 8, 2023Business Services
READING, ENGLAND – Wednesday 8th February 2023. Sanofi announced today that healthcare specialists and patients living with Pompe disease will …
Scottish biotech aims to cure common cold
February 8, 2023Medical Communications
Scottish biotech company ScotBio has announced that it has seen “promising initial results” from its attempts to extract a cure …
Johnson & Johnson’s Ethicon undertakes first robot-assisted kidney stone removal
February 8, 2023Research and Development
Johnson & Johnson (J&J) medtech company, Ethicon, has announced its first robotic-assisted kidney stone removal using its Monarch platform. The …
US Department of Justice asks Third Circuit to reinstate conspiracy charges again KVK
February 8, 2023Manufacturing and Production
The US Department of Justice (DoJ) encouraged the Third Circuit to reinstate ‘conspiracy to defraud’ charges against Philadelphia-based generic drug …
Sandoz files Amgen biosimilar drug for osteoporosis
February 8, 2023Research and Development
Switzerland-based Sandoz has filed a proposed biosimilar of Amgen’s osteoporosis drug Prolia/Xgeva with the FDA. According to Sandoz, over 10 …
Cell and Gene Therapy Catapult to play significant role in establishing one of the largest life sciences campuses in Europe
February 8, 2023Business Services
London, 8th February 2023: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in …
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 8, 2023Business Services
Ghent, Belgium – 08 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
AstraZeneca’s Forxiga approved in EU for chronic heart failure
February 7, 2023Medical Communications
AstraZeneca has announced that its drug, Forxiga, has been approved in the EU for the treatment of symptomatic chronic heart …
Genentech shares positive results from global phase 3 trials for crovalimab in PNH
February 7, 2023Medical Communications
Following the global COMMODORE 2 study, Genentech has announced positive data for crovalimab in treating patients with paroxysmal nocturnal haemoglobinuria …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
